Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Laguna Beach, CA
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Laguna Beach, CA
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
San Diego, CA
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Aventura, FL
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Aventura, FL
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Naples, FL
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Meridian, ID
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Meridian, ID
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Jeffersonville, IN
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Shreveport, LA
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Annapolis, MD
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Annapolis, MD
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Baltimore, MD
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Glen Burnie, MD
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Glen Burnie, MD
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Towson, MD
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Towson, MD
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Missoula, MT
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Missoula, MT
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Brick, NJ
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Brick, NJ
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Garden City, NY
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Garden City, NY
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
New York, NY
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Columbus, OH
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated:  3/9/2017
Clinical Research Facility
mi
from
Dallas, TX
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Status: Enrolling
Updated: 3/9/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Foundation for Cancer Research and Education
mi
from
Phoenix, AZ
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Foundation for Cancer Research and Education
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Tucson
mi
from
Tucson, AZ
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Tucson
mi
from
Tucson, AZ
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Little Rock
mi
from
Little Rock, AR
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Little Rock
mi
from
Little Rock, AR
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Outpatient Clinic - Martinez
mi
from
Martinez, CA
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Outpatient Clinic - Martinez
mi
from
Martinez, CA
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Medical Center of Aurora - South Campus
mi
from
Aurora, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Medical Center of Aurora - South Campus
mi
from
Aurora, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Boulder Community Hospital
mi
from
Boulder, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Memorial Hospital Cancer Center
mi
from
Colorado Springs, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Memorial Hospital Cancer Center
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Penrose Cancer Center at Penrose Hospital
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Porter Adventist Hospital
mi
from
Denver, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
St. Joseph Hospital
mi
from
Denver, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
St. Joseph Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Rocky Mountain Cancer Centers - Denver Rose
mi
from
Denver, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Rocky Mountain Cancer Centers - Denver Rose
mi
from
Denver, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
CCOP - Colorado Cancer Research Program, Incorporated
mi
from
Denver, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
CCOP - Colorado Cancer Research Program, Incorporated
mi
from
Denver, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Swedish Medical Center
mi
from
Englewood, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Hope Cancer Care Center at Longmont United Hospital
mi
from
Longmont, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Hope Cancer Care Center at Longmont United Hospital
mi
from
Longmont, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
St. Mary - Corwin Regional Medical Center
mi
from
Pueblo, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
St. Mary - Corwin Regional Medical Center
mi
from
Pueblo, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Rocky Mountain Cancer Centers - Thornton
mi
from
Thornton, CO
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Rocky Mountain Cancer Centers - Thornton
mi
from
Thornton, CO
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Shands Cancer Center at the University of Florida Health Science Center
mi
from
Gainesville, FL
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Shands Cancer Center at the University of Florida Health Science Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Gulf Coast Cancer Treatment Center
mi
from
Panama City, FL
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Gulf Coast Cancer Treatment Center
mi
from
Panama City, FL
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Tallahassee Memorial Hospital
mi
from
Tallahassee, FL
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Tallahassee Memorial Hospital
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Tampa (Haley)
mi
from
Tampa, FL
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Tampa (Haley)
mi
from
Tampa, FL
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Hines
mi
from
Hines, IL
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Hines
mi
from
Hines, IL
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
John Stoddard Cancer Center at Iowa Methodist Medical Center
mi
from
Des Moines, IA
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
John Stoddard Cancer Center at Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Mercy Cancer Center at Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Mercy Cancer Center at Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
John Stoddard Cancer Center at Iowa Lutheran Hospital
mi
from
Des Moines, IA
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
John Stoddard Cancer Center at Iowa Lutheran Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Wendt Regional Cancer Center at Finley Hospital
mi
from
Dubuque, IA
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Wendt Regional Cancer Center at Finley Hospital
mi
from
Dubuque, IA
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Wichita
mi
from
Wichita, KA
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Lexington
mi
from
Lexington, KY
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Lexington
mi
from
Lexington, KY
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - New Orleans
mi
from
New Orleans, LA
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - New Orleans
mi
from
New Orleans, LA
Click here to add this to my saved trials
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated:  3/9/2017
Veterans Affairs Medical Center - Shreveport
mi
from
Shreveport, LA
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
A Phase III Randomized Study of Patients With High Risk, Hormone-Naive Prostate Cancer: Androgen Blockade With 4 Cycles of Immediate Chemotherapy Versus Androgen Blockade With Delayed Chemotherapy
Status: Enrolling
Updated: 3/9/2017
Veterans Affairs Medical Center - Shreveport
mi
from
Shreveport, LA
Click here to add this to my saved trials